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Abstract 
This review summarises the recent evidence on preope ative therapeutic strategies in 
pancreatic cancer and discusses the rationale for an imminent need for a personalized 
therapeutic approach in non-metastatic disease. The mol cular diversity of pancreatic cancer 
and its influence on prognosis and treatment response, combined with the failure of “all-
comer” treatments to significantly impact on patient outcomes, requires a paradigm shift 
towards a genomic-driven approach. This is particularly important in the preoperative, 
potentially curable setting, where a personalized treatment allocation has the substantial 
potential to reduce pancreatic cancer mortality.  
Keywords 
Pancreatic cancer, preoperative, neoadjuvant, precision medicine, prognostic biomarkers, 
predictive biomarkers 
Highlights 
• Molecular diversity of pancreatic cancer requires a paradigm shift towards a genomic-
driven therapeutic approach 
• Unselected treatment strategies demonstrate only limited efficacy in early-stage 
pancreatic cancer  
• Personalized treatment in non-metastatic disease ha potential to reduce pancreatic 
cancer mortality  
• It is fundamental to implement preoperative clinical studies enriched for potential 
prognostic/predictive biomarkers  
• Novel models of therapeutic development are warranted to accelerate progress in 
pancreatic cancer care and research 
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Introduction 
 Pancreatic cancer (PC) is one of the most lethal solid malignancies and is predicted to 
soon become the second leading cause of cancer mortality in developed countries [1]. 
Estimates of temporal trends for PC incidence and mortality produced by GLOBOCAN 2018, 
indicate a worldwide trend towards a dramatic increase of both incidence (+77.7% with 
356,358 new cases) and mortality (+79.9%, 345,181 deaths) from 2018 to 2040 [2]. This is 
mostly due to our inability to improve prevention ad treatment approaches, despite major 
efforts in preclinical and clinical research that hve marginally impacted patient outcomes 
over the last 50 years. In fact, this incremental progress translates to an increased 5-year 
survival rate from 6% to only 9% in the years 2014-2018, resulting in a mortality/incidence 
ratio of 94% [2]. There is indeed an urgent need to reduce both PC incidence, by 
implementing research on primary and secondary prevention, and mortality, by accelerating 
therapeutic development.  
Surgery with radical intent represents the only potential curative treatment option for PC 
patients; however, only 20% of cases are diagnosed with anatomically resectable disease [3]. 
Notwithstanding substantial improvement in surgical techniques and postoperative outcomes, 
the overall recurrence rate after resection is approximately 85% and the 5-year survival less 
than 30% [4-7]. The best adjuvant chemotherapy regim n (modified FOLFIRINOX, i.e., 5-
fluorouracil, leucovorin, oxaliplatin, and irinotecan) likely adds modest survival benefit in 
all-comers at the expense of a considerable toxicity [7].  The reasons for these poor 
outcomes stem from the inherent aggressiveness of PC, that lends it to be defined as 
“metastatic ab-initio” disease, irrespective of the clinical stage.  In fact, up to 26% of 
patients are found with occult metastases during surgical exploration [8], and 
approximately 70% of resected cases have nodal invovement on pathology after surgery 
[9]. Furthermore, despite the importance of adjuvant therapy, studies demonstrated that up 
to 45% of patients are not able to receive the treatm nt after resection due to poor 
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performance status, postoperative morbidity, or early p ogression of disease [10, 11]. 
Besides, fully completed adjuvant chemotherapy is an independent prognostic factor for 
survival after resection; however, only 55-75% of those who initiate adjuvant therapy 
complete the treatment [12]. In this context, increasing interest has been driven towards 
primary systemic treatments, initially investigated in borderline resectable and locally 
advanced PC with induction/cytoreductive intent [13, 4] and, more recently, applied to 
patients with resectable disease as a pure neoadjuvant (NAT) strategy [15, 16]. 
Preoperative treatment has been associated with several potential benefits including: in-vivo 
chemosensitivity test, tumour shrinking with decreased nodal involvement, increased margin-
negative resection rates, early treatment of occult micrometastases, improved compliance 
with chemotherapy, improved survival after curative resection, and better selection of 
patients who are more likely to benefit from surgery  [17-20]. However, the role of NAT in 
PC is still debated due to a relative lack of robust clinical trial data supporting this approach 
[21-23]. Particularly, several barriers have limited its application and data interpretation 
including the low response rate to chemotherapy in metastatic disease, the difficulty to assess 
the impact of pathologic complete response (pCR) on survival in retrospective studies, the 
inaccuracy of radiological modalities to adequately define the therapeutic response, and the 
poor interobserver agreement in defining baseline res ctability status [23-25].  
 
Preoperative therapy in PC: state of the art  
 Preoperative treatments, including chemotherapy and radiotherapy, have been 
investigated in the three different clinical scenarios of non-metastatic PC: borderline 
resectable, locally advanced unresectable, and resectabl  disease, as defined in Table 1  [26-
31]. 
 In borderline resectable PC the use of NAT has been associated with increased radical 
resection rates and superior overall survival in meta-analysis including cohort studies, 
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retrospective observations, and phase I/II clinical tri ls [32, 33].  More recently, the first 
randomized phase III trial conducted in this setting (the Dutch PREOPANC trial), comparing 
preoperative chemoradiotherapy versus immediate surgery in patients with resectable or 
borderline resectable PC, showed that patients with borderline resectable tumours had 
significantly improved overall survival (OS), disea-free survival (DFS), and locoregional 
failure–free interval (LFFI) for preoperative chemoradiotherapy [34].  
 In resectable disease the effectiveness of NAT is still uncertain, with conflicting 
results on survival benefit compared with upfront surgery [3, 35].  In one of the largest 
retrospective studies comparing NAT followed by resection and upfront resection, the NAT 
group was associated with improved survival compared with standard strategy (median 
survival, 26 months vs 21 months, respectively, HR 0.72; 95% CI, 0.68-0.78). Patients in the 
upfront resected group had statistically significant higher pathologic T stage, positive lymph 
nodes, and positive resection margin. Compared witha subset of upfront resected patients 
who received adjuvant therapy, NAT patients had a better survival (HR 0.83; 95% CI, 0.73-
0.89) [18]. In addition, two recent systematic reviews and meta-analyses investigated the 
survival gain of NAT over standard treatment in patients with resectable tumour. Despite 
the significant improvement of radical resection rate, and the reduction of lymph nodes 
involvement, these studies did not show sufficient vidence for survival benefit of NAT 
when compared with up-front surgery (HR 0.96; 95% CI, 0.82–1.12 [15] and HR 0.86; 
95% CI, 0.73–1.03[21]). However, in Lee et al., thesubgroup of patients who completed 
NAT with subsequent resection had significantly increased survival than surgery followed 
by adjuvant treatment (HR 0.82; 95% CI, 0.71–0.93)[15].  Thus, a marginal favourable 
outcome in patients treated with NAT compared to those treated with the standard strategy 
may support this approach in resectable tumours. Despite these promising data, further 
randomized prospective studies are necessary to clearly stablish the role of NAT in 
resectable PC.  
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 The situation is different for patients with locally advanced unresectable tumours 
where systemic cytotoxic therapy is considered the first-choice treatment modality [31]. 
Conversion surgery should be considered at multidiscipl nary meetings and proposed in 
selected cases with optimal response after induction treatment, and only in specialized 
institutions. In a patient-level meta-analysis conducted on patients with locally advanced PC 
who underwent surgical resection after induction FOL IRINOX, the percentage of 
conversion surgery ranged from 0–43% with a pooled p rcentage of 26% and an R0 rate 
between 50–100% [36]. Due to conflicting results, it is still debatable whether patients should 
receive further ‘local regional’ therapy such as sequential chemoradiation or stereotactic body 
radiation therapy (SBRT) following induction chemotherapy [37, 38].  
 To summarize, current guidelines recommend NAT for b derline resectable PC, 
while upfront surgery followed by adjuvant treatment is still the standard recommendation 
for resectable disease except in cases that are high-risk for  major abdominal surgery or in 
patients with high-risk characteristics (i.e. suspicious of advanced disease based on imaging 
findings or on significantly elevated Carbohydrate Antigen 19-9, large primary tumours or 
regional lymph nodes involvement, uncontrolled pain or excessive weight loss)[39-41] 
(Table 1).  
 In locally advanced unresectable PC primary systemic therapy constitutes the initial 
choice, and in some cases the addition of loco-regional therapy can be considered for local 
control [36, 42, 43] (Table 1).  
 Guidelines suggest the following options for preoprative treatment:  
FOLFIRINOX, modified FOLFIRINOX (m-FOLFIRINOX), gemcitabine, or 
gemcitabine/nab-paclitaxel [39-41, 44]. Multimodal treatment with chemo-radiotherapy 
can be considered in selected cases, but the conclusions about its efficacy are controversial 
[9, 13, 37, 45-47]. Additional strategies such as  perioperative treatments showed early 
promising results but need further investigation [48].  
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 Importantly, when preoperative therapy is indicated, current guidelines advice to refer 
patients to high-volume centres and encourage the partici ation in clinical trials considering 
the limited evidence to recommend specific neoadjuvant regimens off-study [39].  
 
It is worth underlying that the above-mentioned recommendations on preoperative treatment 
in non-metastatic PC produced by the most important international cancer societies, are based 
on systematic reviews of cohort studies (Oxford Levels of Evidence category 2A) due to the 
lack of large phase III randomised controlled trials conducted in this setting [39-41, 44].   
Additionally, results of published studies are often confounded by low patient numbers and 
lack of consensus regarding the definition of what precisely constitutes resectable, borderline 
resectable, and locally advanced - unresectable - disease [49]. Thus, considering the overall 
lack of high quality data from randomized controlled trials, several queries still need to be 
addressed such the optimal candidates to preoperativ  treatment, the optimal treatment and 
number of therapeutic cycles, the timing of surgery after treatment, the additional benefit 
of sequential postoperative therapy (perioperative strategy), as well as the role of 
radiotherapy [50].  
 
Clinical relevance of PC molecular subtyping  
 To date, all available evidence on preoperative treatment relies on studies with a 
“one-size-fits-all” design, without the use of a prognostic or predictive biomarker-based 
selection process. This “all comers” approach has widely characterized the drug development 
process in PC and has been associated with a seriesof failures during the last 50 years, with 
only modest gain in survival obtained with polychemotherapy regimens in undefined patients 
subgroups [51]. Recent insights from modern Next-Generation sequencing (NGS) 
technologies, shed light on the biological rationale of the disappointing results achieved so 
far. Indeed, PC is characterized by high molecular heterogeneity which results in different 
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clinical behaviours among patients with similar tumour characteristics and presentation, 
including prognosis and treatment response/resistance [52-54]. Over the last decade, several 
attempts to subtype PC based on commonly altered molecular networks have been made. 
This has led to the identification of subgroups based on genomic and transcriptomic 
analysis, sharing similar biological and clinical characteristics.  
 Genomic subtypes 
The whole genome sequencing  (WGS) allowed the classification of PC in four subtypes 
according to the frequency and distribution of structural variation of the genome: stable 
genomes (<50 structural variants per genome); scattered genomes (50–200 structural variants 
per genome); locally rearranged genomes (>200 structural variants clustered on <3 
chromosomes); or unstable genomes (>200 structural va iants distributed across the genome) 
(Figure 1) [53]. One of the most clinically meaningful sub-class resulting from this 
classification is represented by unstable tumours.  Interestingly, in this group, a number of 
structural variants > 558 was associated with significant defects in DNA damage response 
(DDR), particularly in homologous recombination repair (HRR) system. Additionally, 
genomic instability co-segregated with inactivation f DNA maintenance genes (BRCA1, 
BRCA2 or PALB2) and a mutational signature of DDR deficiency [53]. Overall, alterations in 
DDR/HRR pathway were found in 24% of patients and were associated retrospectively with 
response to platinum-based chemotherapy [53]. This finding had important clinical 
implications as defined homologous recombination deficiency (HRD) as potential biomarker 
of therapeutic vulnerability to DNA damage agents, such as platinum and poly-ADP ribose 
polymerase inhibitors (PARPi) [55-60].  
Importantly, within HRD, germline mutations in BRCA1 and BRCA2 genes (which are the 
best characterized cause of HRD) have been associated with response to the PARP inhibitor 
olaparib in a phase III clinical trial (POLO) conducted in metastatic, platinum sensitive, PC 
patients (first line setting) [61].  This was the first phase III trial that targeted a clinically 
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relevant predictive biomarker in PC. This resulted in practice-changing governance with the 
approval of olaparib as maintenance strategy in platinum-sensitive advanced PC patients 
with BRCA germline mutations by the United States Food and Drug Administration (FDA) 
and European Medicines Agency (EMA). Several other rials are investigating PARPi in 
metastatic PC patients including those with germline and somatic mutations not only in 
BRCA, but also in other HRD genes [59, 60]. 
It has also been documented that a small proportion of PC (1-2%) has defects in the DNA 
response process resulting from  dysfunctions in DNA mismatch repair (MMR). These 
tumours demonstrate microsatellite instability (MSI), which can be reliably detected by 
routine immunohistochemical assays for MSH1, PMS2, MLH1 and MSH6 expression, and 
can potentially be treated with immune checkpoint blockade therapy [62].  
 Transcriptomic subtypes 
More recently, PC has been classified by multiple groups using associated transcriptional 
networks that proposed several different but overlapping classifications (Table 2 and 
Figure 2)  [63, 64]. Collisson et al. identified three molecular subtypes using hybridization 
array-based mRNA expression: Classical, Quasi-mesenchymal (QM-PDA) and Exocrine-like 
[65]. The Classical subtype expressed GATA6 (the endodermal lineage-specifying 
transcription factor) and exhibited KRAS dependency while QM-PDA subtype correlated 
with high tumour grade and poor prognoses [65]. Similarly, Moffitt et al., identified two 
tumour subtypes (Basal-like and Classical) and two str mal subtypes (Normal and Activated) 
as result of non-negative matrix factorization (NMF) and virtual microdissection of 
microarray and RNAseq data from primary and metastatic PC tumours [66]. This study 
showed that classical subtype was associated with bet er outcome compared to the basal one, 
instead characterized by worse survival and potentially larger benefit from adjuvant 
chemotherapy.  
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Additionally, the Australian PC Genome Initiative (APGI; 
http://www.pancreaticcancer.net.au), as part of the Int rnational Cancer Genome Consortium 
(ICGC), defined four subtypes of PC through an integrated genomic analysis of 
transcriptomes, methylome, mutational and histopathology data: Squamous, Pancreatic 
Progenitor, Immunogenic and Aberrantly Differentiated Endocrine Exocrine (ADEX) [54]. In 
this study, the squamous subtype resulted enriched for gene programmes described in 
squamous-like tumours of breast, bladder, lung, andhead and neck cancers, including 
inflammation, hypoxia response, metabolic programming, and TGF-β signalling [67]. It 
overlapped with histopathologic adenosquamous tumours and was characterized by poor 
survival. Instead, the pancreatic progenitor subtype correlated with better outcome and 
expressed pathways involved in pancreatic endodermal differentiation. The ADEX group (a 
subclass of Pancreatic Progenitor tumours) were defined by transcriptional networks 
characterized by the simultaneous expression of transc iptional programs observed in the 
endocrine and exocrine pancreas, typically activated in the later stages of pancreatic 
development and differentiation.  
Lastly, the Immunogenic subtype, described by extending the analysis to the transcriptome of 
the immune infiltrate in the tumour microenvironment, was enriched for molecular signalling 
involved in immune cell infiltration and related immune response pathways [54].   
 Despite discrepancies in nomenclatures and methods of identification, a substantial 
overlap exists between the different classifications with two main clinically relevant 
subgroups identified: squamous/basal-like and classi l tumours (Figure 2). Squamous and 
basal-like (and QM-PDA) phenotypes share important aspects including the correlation with 
high tumour grade, metastatic disease, chemoresistance nd poor prognosis [57, 66, 68, 69]. 
On the other side, classical subtypes have generally a more favourable clinical outcome. 
These differences have also been documented in the recent genomics-driven COMPASS trial 
for advanced PC, which investigated the correlation between the therapeutic response to 
Jo
urn
al 
Pr
e-p
roo
f
 11
different treatment regimens and the transcriptomic profile obtained through tumour biopsy 
and RNA sequencing [69]. The results of this study showed an overall response rate of 10% 
for basal-like and of 33% for classical tumours (p=0.02) [69]. Notably, in patients treated 
with m-FOLFIRINOX, the progression rate was 60% in basal-like tumours compared to 15% 
in classical PC (p= 0.0002), with median OS of 5.9 months and 9.3 months for basal-like and 
classical respectively (HR 0.47; 95% CI, 0.32-0.69, p=0.0001) [69]. The expression of 
GATA6 has been proposed as a surrogate biomarker for the differentiation between basal-like 
and classic subtype, based on the observation that bas l-like tumours have significantly lower 
levels of GATA6 [57, 68, 69]. However, whether GATA6-low can be used as a predictive 
biomarker of therapeutic response needs further investigation [57, 70, 71]. 
An additional clinically relevant PC subtype is the immunogenic, enriched with infiltrating 
cytotoxic CD8+ T cells, regulatory T and B cells, and high expression of cytotoxic T-
lymphocyte–associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) immune 
checkpoint proteins. In tumours with these molecular characteristics, there is a biological 
rationale for the investigation of immune modulation with checkpoint inhibitors [39].   
  
The rationale for a precision preoperative medicine approach  
 Considering the significant molecular heterogeneity of PC and the related prognostic 
and therapeutic implications, it is of utmost importance to implement biomarker-based 
preoperative clinical trials in order to validate prognostic and predictive factors, fundamental 
for an effective precision medicine approach. On one side, this would allow better risk 
stratification of candidates to up-front resection. On the other side, a genomic-driven 
precision approach may provide instruments useful for the choice of the optimal primary 
systemic treatment, by identifying biomarkers that could predict sensitivity or resistance to 
specific therapies. It is only through an integrated analysis of molecular prognostic/predictive 
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biomarkers and clinical parameters that an individualized treatment path can be implemented 
in non-metastatic PC with the high potential to impact on therapeutic response, radical 
resection rate, and on survival (Figure 3).  
 As previously mentioned, the current decision algorithm in preoperative setting is 
predominantly based on imaging, clinical features, and blood-tests and doesn’t incorporate 
the tumour's biologic aggressiveness, chemoresistance, or metastatic propensity [39]. 
Indeed, no biomarkers that predict treatment efficacy or resistance are currently available 
and robust prognostication models are still lacking. Recently, a preoperative prediction 
nomogram incorporating two biomarkers (S100A2 and S100A4), and clinical variables 
including age, tumour size, and location was develop d and independently validated but its 
use in clinical practice is limited [72]. Interestingly, preliminary results from a randomized 
phase II SWOG S1505 trial of perioperative m-FOLFIRINOX vs. gemcitabine/nab-
paclitaxel in resectable PC, showed similar results in terms of outcomes between the two 
therapeutic strategies thus indicating that in unselect d populations is almost impossible to 
see differences between different regimens as well as to assess the relative role of 
platinum compounds versus other agents [48].  
 It is therefore evident that precision medicine in non-metastatic PC remains an 
urgent and unmet need. Tailoring the therapeutic strategy on the molecular profile in 
preoperative setting is instead fundamental to improving outcome. Published studies 
reported exceptional responses after NAT, translating in long-term survival, in approximately 
30% of patients [73-78], while 17% to 30% of cases progress during the therapy and up to 
38% have no response [32, 79]. Progression during NAT likely reflects a more aggressive 
disease phenotype and has been empirically proposed as an indirect identifier of patients who 
will have limited benefit from curative surgery because of the high probability of relapse 
after resection [80]. However, there is growing evid nce that response to NAT is a crucial 
determinant of long term prognosis and that primary chemoresistance reflects sub-optimal 
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treatment for the majority of patients [76, 81, 82]. The optimal treatment strategy for 
aggressive, chemotherapy resistant tumours is challenging and needs to be defined. Data 
from a recent study showed that genetic or pharmacological depletion of histone 
methyltransferase Enhancer of Zeste Homologue 2 (EZH2) can increase GATA6 expression, 
thus inducing a subtype-switching in favour of a less aggressive, and potentially more 
therapy-susceptible, classical PC subtype [83]. This may represent a promising strategy to be 
further investigated in squamous/basal-like tumours.  
 Alternatively, improvements in response rates and in clinical outcomes observed in 
exceptional and major responders are due to the effects of small subgroups of chemotherapy 
sensitive patients [32, 84]. For example, we can speculate that the response rate reported in 
patients treated with platinum-salts (approximately 30%) [14, 85], reflects a molecular 
background characterized by DDR/HRD (reported in up to 35% of early stage PC patients) 
that has been associated with higher sensitivity to platinum-based chemotherapy [53, 55-57, 
86]. The identification of these subjects is important as the treatment with a platinum-
backbone regimen would be more appropriate for those patients than gemcitabine-based 
chemotherapy [58]. Furthermore, even in the presence of locally advanced unresectable 
tumours, the goal of treatment should be curative surgery in patients with HRD genome as 
treatment with a platinum-backbone regimen in these subjects is likely to result in higher 
response rates than gemcitabine-based chemotherapy, and is thus more likely to result in 
better outcomes and higher surgical resection rates [53, 58]. The ability to undergo tumour 
resection after primary systemic therapy is important as it constitutes the best chance of long 
term survival for locally advanced PC compared with eit er no surgery or local procedures 
(HR 0.39; 95% CI, 0.34–0.46; p < 0.001) [87]. Thus, maximizing the identification of likely 
platinum responders is fundamental considering the potentially significant impact on 
prognosis. However, whether HRD can predict response to platinum in early stage disease 
needs further investigation as the majority of evidnce derives from metastatic setting. It is 
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indeed possible that  different biological features b tween early stage and advanced PC may 
result in different therapeutic susceptibility among tumours with similar molecular profile 
[55].  
 Several novel potential therapeutic targets are currently under investigation in 
metastatic PC and many others are on the horizon (Table 3) [88]. To date, the most clinically 
meaningful biomarkers that have potential to be successfully translated into the preoperative 
setting and incorporated in the design of future clinical trials are germline BRCA1/2 
mutations, HRD (more in general), and MSI. Prognostic biomarkers, such as 
S100A2/S100A4 and GATA6 (to differentiate classical from squamous tumours) should be 
considered (Figure 4). 
 
Challenges in implementing precision medicine in early-stage pancreatic cancer 
 The clinical relevance of preclinical data supporting a precision oncology approach 
needs to be validated in the clinic through biomarker-driven clinical trials. However, several 
hurdles limit implementation, including technical, organizational, and economic barriers  [89, 
90]. There is concern about the ability of local pancreatic biopsy, especially using endoscopic 
ultrasound with fine needle aspiration (EUS-FNA), to obtain sufficient tissue for molecular 
profiling [91]. Furthermore, low cellularity and abundant stroma, typical of PC biopsies, 
often hamper the possibility to perform additional analysis beyond cyto/histopathology [92]. 
The highly spatial intratumoural heterogeneity of PC also prevents obtaining a reliable 
molecular characterization, representative of the entire tumour [93, 94]. In addition to these 
technical challenges, a few other interrelated factors hinder the successful clinical 
implementation of precision medicine in PC. Health systems face an overall lack of 
bioinformatics capacity specialized in the analysis and interpretation of complex data 
obtained from tumour sequencing. Furthermore, despit  evidence of better outcomes for PC 
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patients managed in high-volume centres [95, 96], the vast majority are still diagnosed and 
treated at community hospitals where access to molecular analysis is limited and practicing 
oncologists have little or no training to successfully se the information for clinical decision-
making [89]. Conversely, the centralization of current clinical implementation of multiomics 
technologies in highly specialised tertiary cancer ntres poses important considerations 
about disparities of access to cutting-edge cancer programs. The situation is further 
complicated by the lack of biomarker-based clinical trials for PC patients, challenges in 
conducting adequately powered clinical trials in small molecular subgroups, the turnaround 
timing, costs/effectiveness and reimbursement of molecular analyses. Recently, innovative 
therapeutic development platforms have been developed with the aim of integrating 
molecular data in clinical trials and accelerating precision therapeutic development for PC 
patients. These include PRECISION-Panc in the UK, EPPIC (Enhanced Pancreatic Cancer 
Profiling for Individualized Care) in Canada, and Precision Promise in the USA, which 
represent a possible solution to overcome the challenges mentioned above. These platforms 
aim to integrate discovery with preclinical development and innovative clinical trial design, 
allowing forward and backward translation [73, 97]. As part of PRECISION-Panc, to 
facilitate real world personalised clinical trials, a dynamic and flexible tissue acquisition and 
molecular profiling pathway has been developed (thePRECISION-Panc Master Protocol). 
This approach, based on extra passes on EUS pancreatic biopsy and peripheral venous 
sampling of blood for integrated multiomic analysis, delivers molecular profiling in patients 
with all stages of PC with a success rate of over 80% [98].  The molecular information may 
guide eligibility for enrolment in a PRIMUS trial (Pancreatic Cancer Individualised Multi-
arm Umbrella Study), investigating different biomarker-based treatment options.  
A few other experiences have demonstrated the feasibility and the utility of molecular 
profiling in driving therapeutic choice in patients metastatic PC, with positive impact on 
survival outcomes [56, 57, 99-101]. It has been demonstrated that a molecular-driven 
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precision medicine can be safely integrated into clinical management of PC patients with 
rapid turnaround time (under 30 days) [56, 57, 99-101]. Thus, the incorporation of preclinical 
data for prognostic/predictive assessment in early-stage PC seems to be compatible with 
current standards. Indeed, the median waiting time from surgical consultation to surgery in 
high-volume centres is 29-31 days and potential delays in accessing to surgery would seem 
not to negatively affect pathological features and survival of most patients [102, 103]. In 
addition, data from the US National Cancer Database (2003–2011), including 14,807 resected 
PC patients, indicate that an early allocation of surgery, within 12 weeks from diagnosis, is 
not associated with a survival benefit [104]. 
 
From hypothesis generating to clinical applicability  
 The next step is to advance this promising strategy in the preoperative setting, where 
precision medicine is still an unmet and urgent need. Amongst the emerging plethora of 
potential therapeutic vulnerabilities in PC, the most promising target is represented by the 
homologous recombination deficiency (HRD) pathway. The clinical relevance of this 
molecular characteristic in patients with early stage PC has been recently pointed out in two 
retrospective studies. Golan et al., showed that patients with borderline resectable PC 
carrying germline BRCA mutations have an increased chance for pCR than those wild type 
after neoadjuvant FOLFIRINOX (44.4% vs. 10%, respectiv ly; p= 0.009). Furthermore, the 
median OS after surgery was not reached among patients with germline mutations at 32 
months for BRCA non-carriers (p= 0.2) [81]. This is consistent with other data reported in 
literature in which pCR was associated with better DFS and OS after surgery [75]. Similarly, 
Yu et al. retrospectively studied patients with resected PC and a pathogenic germline 
mutation in BRCA1, BRCA2, and PALB2 [105]. Median OS in mutation carriers exposed to 
platinum in the perioperative setting was not reachd versus 23.1 months in wild type patients 
(HR 0.12; 95% CI, 0.01-1.00). Patients in the mutation-positive group who received 
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perioperative treatment with platinum had a trend toward improved median OS compared 
with those who did not (HR 0.15; 95% CI, 0.02-1.23; P = .07). Despite the retrospective 
design, these studies highlight the importance of a biomarker-driven treatment in the 
preoperative setting as it can guide the therapeutic choice in a personalized manner and can 
significantly improve patient outcomes.  However, to the best of our knowledge, there are no 
prospective neoadjuvant clinical trials evaluating BRCA mutations as predictive biomarker in 
PC (aside from locally advanced unresectable disease, which is usually included in clinical 
trials for advanced PC).  
Currently, only a few trials are using a biomarker-en iched design in the neoadjuvant setting 
(summarized in Table 5). An ongoing prospective trial (PRIMUS002, NCT04176952) 
conducted in the context of PRECISION-Panc [97] is investigating the potential predictive 
role of DNA damage repair (DDR) deficiency in patien s treated with NAT. This is an 
integrated, open label, non-randomized, phase II study examining two therapeutic regimens 
(FOLFOX-A, i.e. 5-FU/LV, oxaliplatin, nab-paclitaxel and gemcitabine/nab-paclitaxel) 
given for 3 months prior to surgery in resectable and borderline resectable PC, aimed at 
assessing efficacy and toxicity with integrated transl tional work. Indeed, the study is 
powered to test a proposed DDR-deficient biomarker for esponse rate in patients treated with 
FOLFOX-A regimen. Particularly, this biomarker is a c ndidate HRD signature hypothesized 
to be a predictor of response to platinum-based therapy, and derived from specific pattern of 
genomic structural rearrangements seen in known HRD cancers, from published and 
unpublished data sets [73, 106]. An additional phase II randomised study (PRIMUS-005, 
STAR-PAC2) will soon be activated and will investigate all-trans-retinoic-acid (ATRA) as a 
stromal targeting agent in a novel drug combination in locally advanced unresectable PC 
[107].   
 Another important biomarker-enriched study is investigating the association between 
MEK inhibitor cobimetinib and PARP inhibitor olaparib in different clinical scenarios, 
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including NAT setting (NCT04005690). This is a phase II feasibility study in which 
validation of cobimetinib and olaparib molecular targets will be explored with tissue 
collection before and after therapy for biomarker evaluation. Several predictive biomarkers of 
therapeutic sensitivity/resistance are investigated; however, detailed information is not 
available from study's description (https://clinicaltri ls.gov/ct2/show/NCT04005690).   
 PARP inhibition is also being investigated in association with chemo-radiotherapy in 
localized PC. The rationale for this approach is provided by preclinical studies, which 
showed remarkable synergy between radiotherapy and PARP1/2i veliparib in orthotopic 
animal models of non-metastatic PC [108]. A recent phase I trial investigated safety and 
clinical efficacy of veliparib combined with gemcitabine-based chemoradiation in thirty 
locally advanced PC patients (NCT01908478) with transl tional analyses. The regimen was 
safe, tolerable, and clinically active [109]. Median PFS and OS of the whole cohort were 
9.8 months (95% CI: 8.4–18.6) and 14.6 months (95% CI: 11.6–21.8), respectively. Median 
OS was 19 months (95% CI: 6.2–27.2) in patients with impaired DDR tumours and 
14 months (95% CI: 10.0–21.8) in patients with DDR proficient tumours. Expression of the 
DDR transcripts PARP3 and RBX1 were associated withimproved OS [109]. Despite the 
promising results showed in this study, further evid nce is warranted to confirm the activity 
and efficacy of this multimodality strategy in poten ially resectable patients.   
Lastly, the PIONEER-Panc Phase II randomized clinical trial (NCT04481204) will 
investigate novel therapeutic approaches in three clinical stage groups of localized PC based 
on Bayesian platform design. This trial entails exploratory translational multiomics analyses 
and organoids-based in vitro drug testing that will provide important information for the 
design of future biomarker-based phase III trials.  
 
Conclusions 
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 The current knowledge on the molecular heterogeneity of PC poses important 
considerations about the future management of patients with non-metastatic disease. Firstly, 
the clinical investigation and validation of putative molecular prognostic biomarkers is 
imperative to identify the subset of patients who wuld benefit most from preoperative 
treatment rather than from upfront surgery. In parallel, it is fundamental to design genomic-
driven clinical trials in order to test predictive biomarkers necessary to match the candidates 
to primary systemic therapy, tailored on the tumour molecular profile, thus allowing the 
opportunity for better treatment and survival outcomes. Furthermore, considering the relative 
rarity of non-metastatic disease, the possibility to significantly impact on the natural disease 
history with an optimal treatment strategy, and the surgical challenges on the definition of 
borderline resectable/resectable/locally advanced disease, it is advisable to refer these 
patients to high volume centres with extensive expertise.  Besides, due to the lack of high-
quality data from randomized controlled trials, every candidate for preoperative treatments 
should be evaluated for enrolment in randomized (ideally molecularly-driven) clinical trials 
to guarantee the best therapeutic opportunity. Lastly, novel models of therapeutic 
development are warranted to investigate multiple hypothesis in small molecular subgroups, 
to accelerate the drug testing process and approval, and maximise the networking of centres 
with available clinical protocols, with possible referral to central high-volume institutes. It is 
only through major efforts in implementing a precision medicine approach that we can 
improve survival of PC patients. 
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Figures legends 
Figure 1. Whole-genome characterization of pancreatic cancer 
Subtypes of pancreatic cancer based on the number and pattern of chromosomal structural variants (SV). The coloured outer 
rings are chromosomes, the next ring represents copy-number changes (red = gain, green = loss), the following represents 
allele frequency. The inner lines represent chromoso e structural rearrangements detected by whole genom  paired 
sequencing and the legend indicates the type of rearrangement. Reprinted by permission from Macmillan Publishers Ltd.: 
Nature 518:495–501, copyright 2015. 
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Figure 2. Phylotranscriptomic tree of pancreatic cancer 
Two initial lineages are evident, largely driven byepigenetic events that separate pancreatic ductal adenocarcinoma into 
Squamous (alternatively named Basal-like and Quasi-mesenchymal) and Classical subtypes.  
The Classical–Pancreatic subtype might contain a spectrum of tumours that resemble pancreatic precursors, paralleling 
lineages occurring during pancreatic development. We can then discern a Classical–Progenitor subtype and, although it is 
unclear as to whether more differentiated progenitor subtypes are due to contamination by normal epithlium, an Aberrantly 
Differentiated Endocrine Exocrine (ADEX) subtype. Although the Immunogenic subtype is largely driven by the immune 
infiltrate of the tumour microenvironment, epithelial-specific mechanisms probably exist that generate such an immune 
response. Stromal subtypes have also been discerned and, currently, do not appear to be directly associated with epithelial 
subtypes. The harmonized nomenclature has two broad subtypes: Squamous and Classical–Pancreatic, with the Classical–
Progenitor and ADEX subtypes residing in the latter. The Classical–Progenitor subtype further subdivides into the 
Immunogenic Progenitor and Pure Classical Progenitor subtypes. Adapted from Collisson EA, Bailey P, Chang DK, Biankin 
AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16: 207-22064, with permission from 
Springer Nature Limited. Copyright © 2019. 
 
Figure 3. Ideal integration of clinical and biological information for personalized 
treatment of non-metastatic pancreatic cancer 
The integration of clinical and pathological features with molecular data from biopsy specimens and blood tests, should be 
used to investigate and validate prognostic/predictive models for personalized treatment selection.  
*Serum CA 19-9 of>500 IU/ml, positive regional lymph node metastases, performance status of 2 or more,comorbidities.  
 
Figure 4. Proposed biomarkers to be implemented in future neoadjuvant clinical trials  
MSI: microsatellite instability; HRD: homologous recombination deficiency, defined by germline or somatic mutations in 
HRD-related genes (BRCA1/2, ATM, PALB2, FANC-genes, RAD51, etc.), COSMIC3 signature, or genomic instability 
through structural variation patterns.  
* NCCN guidelines have been recently updated and recommend universal screening for germline variant in patients with PC, 
regardless of age, ethnicity, and family/personal history of cancer, including not only BRCA1/2 but also ATM, CDKN2A, 
PALB2, STK11, TP53, MLH1, MSH2, MSH6, and PMS2 [31].  
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Table 1. Criteria defining resectability status at diagnosis and associated standard 
treatments 
Resectability 
Status* 
NCCN [31] IAP consensus  [30] Standard Treatment ** 
R 
• No arterial tumour contact (CA, SMA, 
CHA)  
• No tumour contact with the SMV or PV 
or ≤180° contact without vein contour 
irregularity. 
• SMA, CA, CHA: no tumour contac  
• SMV/PV: no tumour contact or 
unilateral narrowing 
 
Surgery followed by adjuvant treatment 
 
Consider staging laparoscopy and 
neoadjuvant therapy, particularly in high-
risk patientsa 
BR 
Pancreatic head/uncinate process: 
• Solid tumour contact with CHA without 
extension to CA or hepatic artery 
bifurcation allowing for safe and complete 
resection and reconstruction. 
• Solid tumour contact with the SMA of 
≤180°    
• Solid tumour contact with variant arterial 
anatomy and the presence and degree of 
tumour contact should be noted if present, 
as it may affect surgical planning.  
Pancreatic body/tail: 
• Solid tumour contact with the CA of 
≤180°  
• Solid tumour contact with the CA of 
>180° without involvement of the aorta 
and with intact and uninvolved 
gastroduodenal artery thereby permitting a 
modified Appleby procedure (some panel 
members prefer these criteria to be in the 
locally advanced category). 
 
• Solid tumour contact with the SMV or 
PV of >180°, contact of ≤180° with 
contour irregularity of the vein or 
thrombosis of the vein but with suitable 
vessel proximal and distal to the site of 
involvement allowing for safe and 
complete resection and vein 
reconstruction.  
• Solid tumour contact with the inferior 
vena cava (IVC). 
Subclassified according to SMV/PV 
involvement alone or arterial invasion. 
BR-PV (SMV/PV involvement alone) 
• SMV/PV: tumour contact 180 or 
greater or bilateral narrowing/occlusion, 
not exceeding the inferior border of the 
duodenum. 
• SMA, CA, CHA: no tumour 
contact/invasion 
 
BR-A (arterial involvement) 
• SMA, CA: tumour contact of less than 
180 without showing deformity/stenosis. 
• CHA: tumour contact without showing 
tumour contact of the PHA and/or CA. 
(Presence of variant arterial anatomy is 
not taken into consideration） 
 
Patients with anatomically resectable 
tumour and with performance status of 2 
or more, CA 19-9 of>500 IU/ml and/or 
positive regional lymph node metastases 
 
 
 
 
 
 
 
 
 
 
 
 
Neoadjuvant therapy followed by surgery  
 
 
Consider staging laparoscopy 
LA 
Unreconstructible SMV/PV due to tumour 
involvement or occlusion (can be due to 
tumour or bland thrombus) 
 
Head/uncinate process:  
• Solid tumour contact with SMA >180° 
• Solid tumour contact with the CA >180°   
Pancreatic body/tail: 
• Solid tumour contact of >180° with the 
SMA or CA 
• Solid tumour contact with the CA and 
aortic involvement 
• SMV/PV: bilateral 
narrowing/occlusion, exceeding the 
inferior border of the duodenum. 
• SMA, CA: tumour contact/invasion of 
180° or more  
• CHA: tumour contact/invasion showing 
tumour contact/invasion of the PHA 
and/or CA. 
• AO: tumour contact or invasion 
• Macroscopic para aortic and extra 
abdominal lymph node metastasis 
(considered as metastatic disease) 
Clinical trial (preferred) 
 
Induction chemotherapy (preferably 4–6 
months) followed by chemoradiation or 
stereotactic body RT (SBRT) in selected 
patients (locally advanced without 
systemic metastases) or chemoradiation, 
or SBRT in selected patients who are not 
candidates for combination therapy 
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Different classifications, based on the anatomic contact on imaging of tumour and blood vessel, have been proposed and adapted over time 
(MD Anderson Cancer Center (MDACC) guidelines [30], the Americas Hepato-Pancreato-Biliary Association/Society of Surgical 
Oncology/Society for Surgery of the Alimentary Tract (AHPBA/SSO/SSAT) expert consensus guidelines [26], the Intergroup Alliance 
[27], the International Study Group of Pancreatic Surgery (ISGPS) criteria [28], and NCCN guidelines [31]. Recently, the consensus 
statement of the International Association of Pancreatology (IAP) added biological and conditional host-related factors to the classification 
based on imaging, including serum CA 19-9 of>500 IU/ml and/or positive regional lymph node metastases, and performance status of 2 or 
more [29].  
 *Decisions about resectability status should be made in consensus at multidisciplinary discussions. 
** Participation in clinical trials is especially encouraged. 
R; resectable; BR: borderline resectable; LA: locally dvanced unresectable; CA: celiac axis; SMA: superior mesenteric artery; CHA: 
common hepatic artery; SMV: superior mesenteric vein; PV: portal vein; IVC: inferior vena cava; AO: aorta; PHA: proper hepatic artery 
a High-risk patients: CA 19-9 more than 500 IU/ml, regional lymph node metastasis (biopsy or PET-CT), poor performance status (Eastern 
Cooperative Oncology Group score = 2, or more).  
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Table 2. Molecular subtyping of pancreatic cancer  
Study 
Histopathology and 
methodology 
Subtypes Biological insight Clinical relevance 
Moffitt et al.66 
 
n=206; 145 primary PDAC and 61 
metastatic PDAC) 
 
mRNA expression microarray (n = 
206; 134 normal sites) and RNAseq  
in 15 primary samples, 37 PDXs, 3  
cell lines and 6 CAFs 
Epithelial:  
Basal-like  
Classical 
 
Stromal: 
Activated  
Normal 
• Different stromal subtypes may explain 
differences in stromal therapy observed 
in preclinical models 
• Metastases retain subtype signature 
• Basal-like subtype in majority of 
metastases 
• Lung metastases associated 
    with Classical subtype 
• Poor survival in Basal-like subtype 
and activated stroma in Classical 
subtype 
• Basal-like subtype benefits from 
adjuvant chemotherapy 
• Stroma-targeted therapies might 
need to be subtype directed 
Collisson et al.65 
 
n = 85 primary untreated PDAC 
 
Microdissected (n = 27), whole  
PDAC (n = 39) and PDCLs (n = 19) 
 
Non-negative matrix factorization  
and consensus clustering 
Classical 
 
Quasi-mesenchymal 
 
Exocrine-like 
• Absence of Exocrine-like subtype in 
ATCC PDAC cell lines 
• Subtype-specific function for GATA6 
and KRAS addiction in Classical subtype 
• Poor survival for Quasi-
mesenchymal subtype, better for 
Classical subtype 
• Quasi-mesenchymal subtype more 
sensitive to gemcitabine 
• Classical subtype 
• More sensitive to erlotinib 
Bailey et al.54 
 
n=266 primary untreated PDAC 
 
Consensus clustering to subtypes 
according to signatures defined by 
Moffitt and Collisson 
 
RNAseq (n = 96) and expression  
array (n = 266) 
 
Squamous 
 
Immunogenic 
 
Pancreatic Progenitor 
 
ADEX 
•  Squamous subtype enriched for 
inflammation, metabolic 
reprogramming, cell proliferation and 
epigenetic downregulation of endodermal 
genes 
•  Squamous and Immunogenic subtypes 
enriched for immune signalling including 
macrophages and T cell subpopulations, 
respectively 
•  Squamous subtype associated with 
adenosquamous histology; Pancreatic 
Progenitor associated with colloid and 
IPMN 
• Poor survival in Squamous subtype 
• Subtype-specific therapeutic targets 
including metabolic and cell cycle 
inhibitors and immunomodulation 
• Myeloid depletion in Squamous 
subtype and immune evasion in 
Immunogenic subtype 
 
PDAC: pancreatic ductal adenocarcinoma; ADEX: Aberrantly Differentiated Endocrine Exocrine; ATCC: American Type Culture 
Collection; CAF: cancer-associated fibroblast; IPMN: intraductal papillary mucinous neoplasm; PDCL: patient-derived cell line; PDX: 
patient-derived xenograft; RNAseq: RNA sequencing; TCGA: The Cancer Genome Atlas. Adapted from Collisson EA, Bailey P, Chang DK, 
Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16: 207-22064, with permission from Springer 
Nature Limited. Copyright © 2019.  
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Table 3. Therapeutic targets in pancreatic cancer 
Therapeutic Target Treatment Study Phase 
BRCA, HRD PARPi, Platinum Phase I-III  
MMRd Immunotherpay * Phase I, II  
HER2/HER3 Zenocutuzumab Phase I, II  
CDK4/6 Palbociclib, PD-0332991 Phase I  
ALK Ceritinib Phase I  
ERK1/2 Ulixertinib, KO-947 Phase I  
TRK/ROS1 Entrectinib, Larotrectinib Phase II  
KRASG12C AMG 510 Phase I  
Metabolism Devimistat, Hydroxychloroquine Phase I-III  
TME PEGPH20, VCN-01, FAK/BTK inhibitors, ATRA Phase I-III  
BRAF MAPK signalling inhibitors  
ATM ATM inhibitors  
ATR ATR inhibitors  
STK11 mTOR inhibitors  
FGFR FGFR inhibitors  
Replication stress ATR, WEE1 inhibitors  
 
Bold: Currently under clinical investigation;  Roman: Preclinical evidence. HRD = Homologous recombination 
deficiency; MMRd = Mismatch repair deficiency; TME = Extracellular tumour microenvironment; ATRA = all-
trans-retinoic-acid; PEGPH20 = pegvorhyaluronidase-α; PARPi= poly-ADP ribose polymerase inhibitors. * 
Immune checkpoint inhibitors, cancer vaccines, and CAR T cell therapy. 
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Table 4. 
Barriers to Implementation of Precision Medicine for Pancreatic Cancer 
Sample-specific Technology-specific Practical/Organizational  Therapeutic development  
Tissue acquisition: 
• Difficult anatomy 
• Small-volume and 
heterogeneous nature of 
samples 
• Ethical considerations of 
repeated biopsies 
 
Tissue analysis: 
• Low cellularity 
• Abundant stroma 
• Intratumoural heterogeneity 
Inconsistency in 
molecular test selection: 
• DNA: targeted-NGS, 
WES, WGS 
• RNA sequencing 
• IHC 
 
Challenges in: 
• Computational analysis  
• Data collection and 
storage  
• Data interpretation 
(actionability)  
• Integration between 
molecular information 
and clinical data 
• Data sharing and data 
mining 
Timing of molecular testing: 
• Time to schedule biopsy 
• Turnaround times for 
molecular test results 
Geographical barriers to 
access precision medicine 
programs   
Lack of bioinformatic 
capacity 
Lack of provider awareness 
and education  
Lack of patient awareness 
Financial concerns: 
• Cost effectiveness 
• Reimbursement 
Identification and validation 
of therapeutic targets 
Lack of specific molecular-
targeted drugs 
Lack of biomarker based 
clinical trials  
Challenges in conducting 
adequately powered clinical 
trials in small molecular 
subgroups 
Primary therapeutic resistance 
 
  NGS: next-generation sequencing; WES: whole exome sequencing; WGS: whole genome sequencing; IHC: Immunohistochemistry.  
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Table 5. Current biomarker enriched preoperative clinical trials in pancreatic cancer 
Trial ID Biomarker Therapeutic Drugs Phase Status 
NCT04176952 HRD signature FOLFOX-A  
Gemcitabine/nab-paclitaxel 
II 
non-randomized  
Recruiting 
NCT04005690 Multiple, not specified  Cobimetinib  
Olaparib 
II 
non-randomized 
Recruiting 
NCT04481204 Multiple, not specified Multiple drugs II 
randomized  
Not yet recruiting 
Clinical trials including (not limited to) patients with resectable/borderline resectable pancreatic cancer. FOLFOX-A: 
5-FU/LV, oxaliplatin, nab-paclitaxel; DDR: DNA damage response; HRD: homologous recombination system 
deficiency.  
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Stable Scattered
Unstable Locally rearranged
30%
200 SV/< 3 chrom; 
focal amplification of 
HER2, FGFR, 
PIK3CA, PIK3R3
20%
<50 SV/genome
widespread aneuploidy
36%
50–200  SV/genome 
14%
>200 SV/genome; 
associated with  
defects in DNA 
maintenance
 
 Intra-chromosomal rearrangement 
  Inter-chromosomal translocation 
  Duplication 
  Tandem duplication 
  Inversion 
  Foldback inversion 
  Amplified inversion 
 
 Deletion 
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ADEX 
Classical–Pancreatic  
Cl
as
sic
al
 - 
Pr
og
en
ito
r  
Sq
ua
m
ou
s 
Pure C
lassical Progenitor  
Bailey et al. 54 
Im
m
un
og
en
ic
	P
ro
ge
ni
to
r	 
Origin 
 
Classifications 
 
Moffit et al. 66 
Collisson et al. 65 
Squamous 
 
Classical-Pancreatic 
 
Classical-Progenitor 
 
Pure Classical 
Progenitor 
 
Immunogenic  
Progenitor 
 
Immunogenic 
 
Squamous 
 
Progenitor 
 
Classical 
 
Quasi-mesenchymal 
 
Basal-like 
 
Classical 
 
Normal stroma 
 
Activated stroma 
 
H
ar
m
on
iz
ed
 N
om
en
cl
at
ur
e 
of
 E
pi
th
el
ia
l s
ub
ty
pe
s 
GATA6 low 
Poor survival 
Activated stroma 
Poorly differentiated 
Chemoresistant 
GATA6 high 
Better survival 
Normal stroma 
Well differentiated 
Chemosensitive 
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Anatomic definition 
of resectability
Biological and 
conditional host-
related factors *
Patient 
Preferences
Biopsy for integrated 
characterization:
• Histopathological
• Molecular 
Personalized  
Treatment
Blood for circulating
biomarkers
Prognostic/Predictive 
Biomarkers
Clinical Decision 
Making
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Tumor Biopsy 
Blood Test  
Histological diagnosis 
 
 
 
Genomic/Transcriptomic profile 
(and other multi-omics analyses) 
 
 
 
Patient-derived tumor organoids 
(molecular characterization and drug 
sensitivity testing) 
 
 
 
 
 
 
 
Universal germline testing for 
detection of pathogenic variant in 
cancer predisposing genes  
(at least BRCA1 and BRCA2*) 
  
Proposed prognostic/predictive biomarkers: 
 
GATA6 
S100A2 and S100A4  
MSI 
HRD  
 
 
 
 
BRCA1 
BRCA2 
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